What's your bottom dollar stock price for Novo - it seems like the market is essentially discounting all of its GLP1 revenue

Relatively simplistic analysis, but if you subtracted out all of Novo's GLP1 revenue in 2025 - about 50% - from its total 2025 revenue you get revenue of about $24 billion.

Novo's current stock price is $44 with a market cap of $150 billion. That's a P/S of 6.2x, EXCLUDING all GLP1 revenue and is generally in line with Novo's rough historical P/S ratio range of 4.5 to 9 in the 2010s.

I know this is a simplistic metric as P/S doesn't factor in the significant hit to net income that would come with all GLP1 revenue going to 0; but, in a simplistic sense, it does seem like the market is essentially valuing the company that way.

Put differently, if you bought Novo now at $44 a share it seems like you're getting their entire GLP1 revenue stream for free - which likely will contract, but it's hard to see one of the market leaders in the GLP1 space revenue going to $0, and there are thesis upsides for it growing since the obesity market is potentially huge even if margins in the are decrease.

I'm curious, what are people's bottom dollar stock price for Novo - that is, the price where it's a no brainer to buy regardless of any GLP1 headwinds? I personally think at or below $40 it really start to give nothing but upside for the GLP1 revenue.